Skip to Content.
Sympa Menu

homestead - [Homestead] Honest reporting of clinical trials

homestead AT lists.ibiblio.org

Subject: Homestead mailing list

List archive

Chronological Thread  
  • From: Tvoivozhd <tvoivozd AT infionline.net>
  • To: homestead AT lists.ibiblio.org
  • Subject: [Homestead] Honest reporting of clinical trials
  • Date: Mon, 13 Sep 2004 17:55:43 -0700

For decades the corrupt pharmaceutical companies have published the results of clinical trials that supported their claims, hidden results of clinical trials that disproved their claims---so they could go right on selling their ineffective or dangerous snake oil, raking in fraudulent multi-millions of dollars.

This is about to change.


NewScientist.com



*Medical journals to require clinical trial registration*


11:18 09 September 04

NewScientist.com news service


Eleven prestigious medical journals around the world have announced a new strategy intended to force drug companies to disclose more information about clinical trials.

The International Committee of Medical Journal Editors (ICMJE) plan to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The new policy will be brought into force over the next year. The group of journals involved includes the /New England Journal of Medicine/, /The Lancet/, and /The Journal of the American Medical Association/.

These registries would describe the size, design and purpose of each trial at its beginning. The policy's aim is to prevent companies from only reporting positive results, or spinning data to suppress inconclusive or unflattering conclusions about their treatments, says Catherine De Angelis, editor-in-chief of JAMA.

All the editors had had stories about clinical results being brought into question "because we knew there were trials out there that were never being reported", she says. While there are hundreds of other medical publications that have not publicly endorsed the plan, De Angelis believes many will. "We already know of several other journals that are going to sign on."

"This is a really exciting development. This will be a motivator for companies, no doubt about it," says Kay Dickersin of the Brown University Center for Clinical Trials and Evidence-based Healthcare in Providence, Rhode Island. But experts like Dickersin also say greater steps are needed to guarantee that the public gets the information it needs.


*High profile lawsuit*

For years, medical advocates have been calling with little effect for biotech and pharmaceutical companies to provide more details about their clinical results. But recently, the issue has been reinvigorated, partly due to the high profile lawsuit brought by New York State attorney general, Eliot Spitzer, against the pharmaceutical giant GlaxoSmithKline.

The suit alleged that the company withheld trial data suggesting that children taking its antidepressant drug Paxil had more suicidal tendencies than children receiving placebos. While the company admitted no wrongdoing, it has agreed to pay a $2.5 million dollar settlement and to post more comprehensive trial results on its website.

As a result, other industry leaders, such as Eli Lilly and Merck announced they would also start registering their results online. And just this week, the Pharmaceutical Research and Manufacturers of America, an industry trade group to which all three companies belong, announced the creation of a database in which its member companies would voluntarily deposit both negative and positive results.

However, an important element of the plan the ICMJE endorses is the requirement that such registries be run by not-for-profit agencies with standards for the validity of the data they contain. The editors cite the database maintained by the US National Library of Medicine - www.clinicaltrials.gov - as an exemplar.

Volunteer, industry-sponsored substitutes will not work, says De Angelis. "Why would you put the fox in charge of the hen house?" she says. "And if they have nothing to hide, why waste money setting up their own database?"


*Enrolling patients*

Another related development this summer came from the American Medical Association, which began urging Institutional Review Boards at hospitals and universities to require trials under review to register their results. All human clinical trials in the US need approval from an IRB in order to start enrolling patients.

But how many IRBs or journals will stand by these new policies is hard to guess. "That's why they're insufficient," says Jim Manley, a spokesperson for US Senator Edward Kennedy who is co-sponsoring a bill requiring companies to report their results. "Voluntary measures by companies, while generally laudable, will not produce the comprehensive information the public needs."

The fate of Edward's bill and similar ones pending is uncertain. The pharmaceutical industry has great political influence in Washington and has traditionally resisted new legal restrictions.

"If we knew for certain a law was coming, we wouldn't even bother with our policy," says De Angelis.



Philip Cohen



Return to news story <http://www.newscientist.com/news/news.jsp?id=ns99996378>



© Copyright Reed Business Information Ltd.








  • [Homestead] Honest reporting of clinical trials, Tvoivozhd, 09/13/2004

Archive powered by MHonArc 2.6.24.

Top of Page